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Background: Serosurveys of biomarkers of infection/vaccination are 
widely used for evaluating vaccine-induced immunity and monitoring 
the effectiveness of immunisation programmes in developed 
countries. In sub-Saharan Africa (sSA) where vaccination coverage (VC) 
estimates are often incomplete, inaccurate and overestimate effective 
population immunity, the use of serosurveys is limited. 
Methods: We conducted a review of the use of serosurveys to 
assess/complement assessments of VC in sSA by searching electronic 
databases (PubMed, Embase, Web of Science, Popline, Ovid and Africa 
Wide Information) for English language articles published from 1st 
January 1940 to 31st January 2017. We also searched the references of 
retrieved articles. SSA was defined as all of Africa excluding the 
countries in North Africa. We included only articles that measured VC 
and assessed the quality of these studies using the Newcastle-Ottawa 
Scale. 
Results: We found 1056 unique records, reviewed 20 eligible studies 
of which just 12 met our inclusion criteria. These 12 studies were 
serosurveys of measles, tetanus, polio and yellow fever. Antibodies 
induced by natural infection confounded serological test results and 
there was significant discordance between vaccination history and the 
presence of antibodies in all except for tetanus vaccine. No study 
looked at Hepatitis B. 
Conclusions: Serosurveys for tetanus or tetanus containing vaccines 
may be directly useful for ascertainment of vaccination exposure or 
reliably complement current survey methods that measure VC. Given 
the limited experience in using serosurveys for this purpose in sSA, 
well-designed serosurveys of tetanus and possibly hepatitis B are 
required to further validate/evaluate their performance.
Open Peer Review




23 Feb 2018 report report report
Heather Scobie, Centers for Disease Control 
and Prevention (CDC) , Atlanta, USA
1. 
Mary E. Ramsay , Public Health England, 
London, UK 
London School of Hygiene & Tropical 
Medicine, London, UK
2. 
William J. Moss , Johns Hopkins 
University, Baltimore, USA
3. 
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 18
Wellcome Open Research 2018, 3:16 Last updated: 25 MAY 2021
Corresponding author: Ifedayo M.O. Adetifa (IAdetifa@kemri-wellcome.org)
Author roles: Wanjiku HW: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; Adetifa 
IMO: Conceptualization, Funding Acquisition, Methodology, Resources, Supervision, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: HW was supported through the DELTAS Africa Initiative [DEL-15-001]. The DELTAS Africa Initiative is an independent 
funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported 
by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome 
Trust [107769] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of 
AAS, NEPAD Agency, Wellcome Trust or the UK government. This research work was not funded by any specific grant from any funding 
agency in the public, commercial or not-for-profit sector.  
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2018 Wanjiku HW and Adetifa IMO. This is an open access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly 
cited.
How to cite this article: Wanjiku HW and Adetifa IMO. Serological Surveys for complementing assessments of vaccination 
coverage in sub-Saharan Africa: A systematic review [version 1; peer review: 3 approved with reservations] Wellcome Open 
Research 2018, 3:16 https://doi.org/10.12688/wellcomeopenres.13880.1
First published: 23 Feb 2018, 3:16 https://doi.org/10.12688/wellcomeopenres.13880.1 
Keywords 
Serosurveys, Serological surveys, crude vaccination coverage, effective 
vaccination coverage, sub-Saharan Africa
 
This article is included in the KEMRI | Wellcome 
Trust gateway.
 
Page 2 of 18
Wellcome Open Research 2018, 3:16 Last updated: 25 MAY 2021
Introduction
Serological surveys (serosurveys) provide invaluable insight into 
the natural history and epidemiology of infection and can be 
used to: assess the effectiveness of vaccine campaigns, determine 
proximity to theoretical thresholds for disease elimination, 
estimate the burden of disease for immunising and/or chronic 
infections, and identify gaps in population immunity to inform 
interventions such as supplementary immunisation activities1–4. 
As a tool in seroepidemiology, serosurveys have been a significant 
component of disease control and elimination strategies for acute 
viral vaccine preventable disease (VPDs) like measles, rubella, and 
polio in high-income countries. They have also been used to dem-
onstrate the continued effectiveness of vaccination programmes5, 
and to guide revisions/adjustments to vaccination strategies for 
pertussis, diphtheria and Haemophillus influenza B (Hib)6–8.
Despite some of the well-known limitations of serological 
surveys, it is believed they can play a role in improving the 
accuracy of estimates of vaccination coverage (VC), or be used 
independently to assess VC particularly in developing countries9. 
Receipt of the third dose of the combined diphtheria, tetanus and 
pertussis vaccine (DPT3) assessed at 1 year of age is currently 
the most widely used proxy for childhood vaccination coverage 
worldwide10. VC is also an indicator of health care delivery, a 
performance metric for national immunisation programmes, 
and a global health target indicator. It is typically obtained from 
administrative records (health facility registers and vaccine doses 
consumed) or household surveys of retained immunisation cards 
and/or caregiver recall of childhood vaccination history. These 
methods have well known limitations that frequently result in 
over- or underestimates of VC9. Since receipt of a vaccine does not 
always induce protective immunity, these methods report a crude 
VC, and there is frequently a gap between crude (beyond those 
related to the intrinsic properties of the vaccine) and effective 
VC given the recurrent outbreaks of VPDs in settings reporting 
high crude VC11,12.
Ideally, overall evaluations of national immunisation programmes 
in low and middle income countries (LMICs) and for effective-
ness of specific vaccination programmes should include direct 
measurement of population immunity in serological surveys. 
Compared to high-income countries, there appears to be very 
limited experience with the use of serological surveys in 
sub-Saharan Africa (sSA) LMICs to complement measures of 
crude VC and determine effective VC or population immunity. 
Consequently, there is very little application of seroepidemiology 
in monitoring the effectiveness of vaccination programmes and 
for informing vaccine policy in sSA.
This overall aim of this study is to assess the extent to 
which serological surveys have been carried out in sSA to 
complement assessments crude VC. We carried out a systematic 
review of studies reporting on vaccinated populations who also had 
samples taken for serological tests with a view of comparing the 
test results to records of vaccination in sSA. 
Methods
Literature search and selection criteria
This review was conducted in accordance with PRISMA guide-
lines (see checklist, Supplementary File 1)13. From 23rd February 
to March 2016, we searched the United States National 
Library of Medicine’s PUBMED, Popline, Ovid, Africa Wide 
Information, EMBASE and the Web of Science™ (Thomas 
Reuters, PA, USA) databases for English-language publications 
reporting the use of serosurveys for classifying vaccination 
history or determining vaccine coverage. We repeated the search 
for the PUBMED database on 30th January 2017 to ensure studies 
published between March 2016 and January 2017 were not 
omitted.
The search query used was (((((serologic tests) OR serologic 
surveys) AND immunization coverage) OR vaccination 
coverage) AND sub-Saharan Africa, which produced the fol-
lowing search details in PUBMED. ((((“serologic tests”[MeSH 
Terms] OR (“serologic”[All Fields] AND “tests”[All Fields]) 
OR “serologic tests”[All Fields]) OR (serologic[All Fields] 
AND (“surveys and questionnaires”[MeSH Terms] OR 
(“surveys”[All Fields] AND “questionnaires”[All Fields]) OR 
“surveys and questionnaires”[All Fields] OR “surveys”[All Fields]))) 
AND ((“immunisation”[All Fields] OR “vaccination”[MeSH Terms] 
OR “vaccination”[All Fields] OR “immunization”[All Fields] OR 
“immunization”[MeSH Terms]) AND (“AHIP Cover”[Journal] 
OR “coverage”[All Fields]))) OR ((“vaccination”[MeSH Terms] 
OR “vaccination”[All Fields]) AND (“AHIP Cover”[Journal] OR 
“coverage”[All Fields]))) AND (“Africa south of the Sahara”[MeSH 
Terms] OR (“Africa”[All Fields] AND “south”[All Fields] 
AND “Sahara”[All Fields]) OR “Africa south of the Sahara”[All 
Fields] OR (“sub”[All Fields] AND “Saharan”[All Fields] AND 
“Africa”[All Fields]) OR “sub Saharan Africa”[All Fields]). 
The same query was used to search the EMBASE database.
We included English language articles reporting primary data 
from a serological survey that included assessments of VC from 
research conducted in sSA. We defined sSA as the whole of 
Africa except Northern Africa. Reviews, reports of serosurveys 
or vaccination coverage alone were not included. Full text cop-
ies of the relevant articles meeting our inclusion criteria were 
obtained. In addition, their references were individually checked 
to identify other related papers meeting the study inclusion criteria 
(see Figure 1). Retrieved citations were extracted to Endnote™ 
X7 (Thomas Reuters, PA, USA). The following variables were 
extracted from each included article- country/setting of study, year 
of study, sample size, age of participants, vaccine administered, 
biological specimen used for serology, type of serological test 
done, numbers who received vaccines from vaccine records 
and numbers of positive serology results. The key outcome of 
interest was vaccination coverage assessed by receipt of vaccines 
compared to results of serological tests.
Quality assessment
As recommended by the Cochrane Public Health Review Group14 
and used in other reviews15, the Newcastle Ottawa Scale (NOS) 
was used to assess the quality of each eligible study, to ascer-
tain the risk of bias; and internal and external validity16. Studies 
were assessed in three domains: selection of the study groups, 
comparability of the study groups, and the ascertainment 
of the outcome of interest and a point system is awarded 
for each item evaluated16. With a total of 10 points, stud-
ies with ≥8, 6–7, 4–5, and ≤3 points respectively were evalu-
ated as very good, good, satisfactory and unsatisfactory studies. 
(see Supplementary File 2).
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Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram showing the outcome of the 
literature search. (sSA – sub-Saharan Africa).
Data synthesis
Since the studies eligible for inclusion in this review were 
few, and showed significant heterogeneity in study design and 
ascertainment of outcomes, a meta-analysis for derivation of 
pooled estimate of effect was not possible. Instead, a narrative 




As shown in Figure 1, literature search yielded 1056 articles 
but only 12 of them were relevant to this review. These 12 were 
from Western (Nigeria17,18, Gambia19, Mali20 and Ivory Coast21); 
Eastern (Ethiopia22,23, Kenya24, Tanzania25, and Sudan26) and 
Southern (Malawi27,28) regions of Africa. There were no stud-
ies from the Central African region. Although there were 
publications from all but one region of sSA, only 9 of 39 countries 
were represented.
The reviewed articles reported serosurveys of 3 viral replicating 
vaccines – polio, measles, yellow fever and one toxoid – 
tetanus (see Table 1). There were a total of 10 studies on 
measles17–19,21–25,28,29, 1 on polio19, 1 on yellow fever26 and 3 on 
tetanus19,20,22. In these surveys, results were compared to vaccination 
history ascertained by caregiver recall, presence of a known 
vaccination scar and/or vaccination record (card or clinic records).
Quality appraisal
Table 2 summarizes the overall and category-specific quality of the 
included studies, along with some limitations. A rating of very good 
was given to three studies21,22,24, majority i.e. 8 studies17,19,20,23,25–28 
were assessed as good while one18 was rated just satisfactory. 
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Measles vaccine
In the study by Breman et al.21 in Cote d’Ivoire, pre-campaign 
vaccination history and crude coverage were determined by 
history of vaccination and/or the presence of a scar following 
smallpox vaccination. The pre-campaign crude VC was 53.6%, 
but serological surveys showed 98.3% (243/247) and 91.7% 
(297/324) of children 6–8 and 9–24 months old respectively lacked 
measles antibodies. About 2.5% of children who reported not hav-
ing received any vaccination had evidence of a vaccination scar. 
Among the children whose families reported a history of measles 
or vaccination before the recent campaign, only 45.5% (27/62) 
had measles antibodies. For susceptible children vaccinated during 
the campaign, 84.3% (107/127) and 94.7% (161/170) of 6–8 month 
and 9–24-month-olds seroconverted respectively.
Three decades later, investigators in Malawi found the same 
discrepancy between vaccination history and serosurvey results27. 
This 2015 study found poor sensitivity and positive predictive 
value (PPV, 75.8% and 79.9% respectively) for vaccination and 
infection history as predictors of positive measles serological 
tests.
Specificity was 10.3% and the negative predictive value (NPV) 
was also poor at 8.3 %27. Although the population in this more 
recent study was older and aged ≥18 months (median age 
37 years), a 2001 study in the same setting reported the same 
discordance between seropositivity and vaccination history 
in 246 children <5 years. Here, 17% (4/23) and 67% (54/81) 
of children aged 8–12 and 12–23 months old were positive for 
measles antibody but the history of measles vaccination was 26% 
and 80% respectively28.
In a Gambian study, antibody test results following routine 
vaccination were compared against the vaccination records 
of 689 children aged 3 to 4 years. Vaccination records were 
retrieved from the Gambia Hepatitis Intervention Study (GHIS) 
main database and missing data obtained from vaccine card 
records during follow-up home visits. They found seroconver-
sion in 91% (608/665) of the children with history of receiving 
the measles vaccine, 25% (14/57) of children without antibodies 
had been vaccinated before the age of 9 months and 7 of 24 chil-
dren who did not receive the vaccine acquired measles antibodies 
possibly through natural infection19. The authors excluded children 
with incomplete vaccination histories either because they could 
not be traced for follow-up home visits or their immunization 
card were lost.
Ogunmekan et al.17 measured measles antibody titres in 204 
Nigerian children aged 6 to 12 months pre- and post-vaccination. 
On follow-up testing 6–8 weeks later, only 53.2% (91/171) of 
children without pre-vaccination antibodies seroconverted. The 
low seroconversion rates were attributed to low potency vac-
cines. No history of measles was given for the 33 children who 
were sero-positive before vaccination. However, in a more recent 
Nigerian report, Fowotade et al.18 reported a significantly higher 
post vaccination seroconversion of 68.8% (196/286) in children 
9–12 months old.
Contrary to the results from Nigeria, a better concordance was 
observed between crude and effective coverage (98.8% (878/889) 
and 94% (836/889) respectively) in Tanzanian children aged 18 
months to 5 years25.
The utility of non-invasive biological specimens specifically 
oral-fluid (OF) for determining measles vaccine coverage was 
investigated by Nigatu W. et al.23 among 1928 children aged 9 
months to 5 years (pre-vaccination) and 745 individuals aged 9 
months to 19 years (post-vaccination). There were differences 
in age-groups sampled pre- and post-vaccination because the 
post-vaccination survey carried out 6 months after the measles 
campaign was aimed at assessing population immunity and 
age susceptibility to measles. The study team documented 
receipt of measles vaccines delivered routinely and/or by sup-
plementary immunisation activities. Pre-vaccination measles 
seroprevalence was 49% (1507/3075) in vaccinated and 21% 
(147/700) in unvaccinated children. The post-vaccination preva-
lence of measles antibodies was 80% in the 0–4 and 5–9 year 
olds, increasing to 96% in the 15–19 year olds as shown in 
Table 1. However, sensitivity of OF for antibody testing declined 
from 95% in individuals with measles IgG ≥1000 mIU/ml to 
75% in individuals with measles IgG ≤1000 mIU/ml. In another 
study conducted in rural Kenya that evaluated the performance 
of OF as a measure of the effectiveness of a measles vaccination 
campaign, the pre-campaign and post-campaign measles 
seroprevalence was 60% (520/866) and 87% (753/866) respec-
tively with a 70% reduction in the prevalence of the susceptible 
population at 85% crude coverage24. In addition, the proportion 
of weakly positive individuals by the assay used increased from 
35% pre-campaign to 54% post-campaign.
Polio vaccine
In the single study of polio vaccine in West Africa, investiga-
tors assessed the effect of supplementary oral polio virus (OPV) 
vaccine doses in Gambian children aged 3 to 4 years19. Blood 
samples were tested for antibodies to polio virus types 1 and 3 using 
the standard polio neutralization assay. Seroprevalence for OPV 
1 and OPV 3 was 81.5% (22/27) and 89% (24/27) respectively 
in children who had 3 recorded vaccine doses.
Yellow Fever vaccine
A household-based sero-epidemiologic survey of all age groups 
was conducted in Sudan after a mass vaccination campaign in 
response to yellow fever (YF) epidemic26. The serosurvey was 
designed to describe the epidemiology of the outbreak and to 
measure YF vaccine coverage. All the 84 (96.6%) and 3 (3.4%) 
individuals who reported having received and not having received 
the vaccines during the campaign respectively, had positive 
serological results for YF IgM antibodies. Of the 3 individuals who 
had positive serologic results despite no history of vaccination, 
2 reported previous YF infection and 1 reported a Chikungunya 
virus-like illness.
Tetanus vaccine
Tapia et al.20 collected serum and oral fluid (OF) from Malian 
infants, toddlers and adults males without a history of tetanus 
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Table 1. Summary of all studies included in the review.




Age group Sample size Vaccine Specimen Crude coverage (%) Effective 
coverage (%)
Travassos et al.22 Ethiopia 2016 12–23 and 
6–8 months
1200 Tetanus Serum 12–23 months 
District 1: 87 
District 2: 41 
District 3: 35 6–8 
months 
District 1: 58 
District 2: 29 
District 3: 40
12–23 months 
District 1: 93 
District 2: 60 
District 3: 53 6–8 
months 
District 1: 68 
District 2: 41 
District 3: 31
Polonsky et al.27 Malawi 2015 8 months to 
29 years 
2106 Measles Serum 62 < 15 years: 92 
15–29 years: 60
Fowotade et al.18 Nigeria 2015 9–12 
months
400 Measles Serum 100 68.8









Measles Oral fluid 85 Pre-campaign: 60 
Post-campaign: 87
Nigatu et al.23 Ethiopia 2008 9 months to 
19 years
1928 Measles Serum Pre-vaccination 
9–65months: 79 
12–23 months: 84 
Post-campaign 
15–71 months: 88 
18–29 months: 87
Pre-vaccination 
9–11 months: 44 
5 years: 60 Post-
campaign 
0–4 years: 80 
5–9 years: 80 
15–19 years: 96






Not Reported Serum:100 
Oral Fluid:79




246 Measles Serum District 1: 84 
District 2: 79
District 1: 80 
District 2: 69
Lyamuya et al.25 Tanzania 1999 18 months 
to 5 years
889 Measles Serum 98.8 94
Fortuin et al.19 Gambia 1995 3–4 years 816 Measles 
Polio 
Tetanus








Nigeria 1981 6 months to 
1 year
224 Measles Serum 100 53.2
Breman et al.21 Ivory 
Coast
1975 0 to 72 
months 
1762 Measles Serum 6–8 months: 54 
9–24 months: 52
Pre-campaign 
6–8 months: 1.6 
9–24 months: 8.3 
Post-campaign 
6–8 months: 84.3 
9–24 months: 94.7
vaccination and measured specific tetanus antitoxin by enzyme-
linked immunosorbent assay in serum (S-ELISA) and OF 
(OF-ELISA). The proportion of infants and adult males (nega-
tive controls) with antibody titres ≥ 0.15 IU/mL (protective level) 
was 100% (33/33) and 17% (6/35) in serum and 95.5% (32/33) 
and 11% (4/35) in OF respectively. All 33 toddlers who received 
all 3 doses DPT vaccine (DPT3) had serum titres ≥ 0.15 IU/mL 
(sensitivity= 100%, PPV= 94.3%) while 26 had OF titres ≥ 0.0015 
IU/mL (sensitivity= 78.8%, PPV= 92.9%). However, titres of teta-
nus antitoxin in OF were a 100-fold lower compared to serum. Test-
ing of serum performed better than OF with a sensitivity, PPV, spe-
cificity and NPV of 91.9%, 100%, 100%, and 73.6% respectively.
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* * * * ** * * * 9






- - * ** - ** - 5












Farnon EC,  
et al. (2010)26
* - - ** * ** * 7





Ohuma EO,  
et al. (2008)24
* * - * ** ** * 8




Nigatu W, et al. 
(2008)23






Tapia MD, et al. 
(2006)20
* - - ** - ** * 6





Takechi M,  
et al. (2001)28






* - - * ** * * 6





Fortuin M,  
et al. (1995)19
* * - ** * * * 7
Selection bias, 
test kit sensitivity 
threshold
Ogunmekan 
DA, et al. 
(1981)17
- - - ** * ** * 6
Convenience 
sample, selection 






* * - * ** ** * 8
Recall bias, 
misclassification
One star (*) is awarded to self-reported or less objectively measured outcomes and two (**) are awarded when outcomes are assessed by independent blind 
observers or with record linkage (see Supplementary File, SF1).
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Discussion
This review confirms the limited use of serosurveys in assess-
ments of or to complement estimates of VC in sSA. We find 
evidence for the utility of serological data for determina-
tions of effective vaccination coverage, despite their inabil-
ity to distinguish population immunity induced by vaccines 
from those resulting from natural infection.
This review also highlights significant gaps between crude and 
effective VC for many vaccines currently in use as reported else-
where23,27,29,30. Clearly, crude VC does not correctly identify all 
the non- or partially immunised disease susceptible population. 
For example, an effective coverage of >95% is required to 
induce sufficiently high herd immunity to interrupt transmis-
sion of measles and this is inferred from the crude VC typically 
derived from administrative records and/or parental recall29,31. 
There are several reasons why there are persistent outbreaks of 
VPDs such as measles in sSA. There is poor coverage resulting 
from poor access to and/or utilization of immunization services. In 
addition, there are evidence of cold chain failures leading to the 
delivery of non-viable/less potent vaccines to those with vacci-
nation records31,32. Without significant improvements to the cold 
chain and crude coverage, many countries in the sub-continent 
will not achieve global and regional vaccination targets required 
to interrupt transmission of many VPDs.
The lower seroconversion rates for measles vaccine in children 
<9 months old may be attributable to interference by maternal 
antibodies22. Lower seroconversion reduces protection post-
vaccination. Since maternal antibodies wane over a period of 
6–12 month33,34, a 2-dose schedule that delivers and achieves 
VC ≥95% for a measles-containing vaccine later in childhood 
(from the 2nd year of life) is now deemed essential to on-going 
control efforts35. Because most cases of measles are subclinical, it 
was not surprising to find that a history of prior contact with or 
measles illness was poorly predictive of serological test results36.
Just like for measles vaccine, reported vaccination and 
previous infection were poor predictors of protective immu-
nity for oral polio. The trivalent oral poliovirus vaccine (tOPV), 
a combination of all 3 types of polioviruses, is the most com-
monly used polio vaccine in routine childhood immunization37. 
Typically, tOPV is administered at 6 weeks or 1st month of life 
at 4 week-intervals along with the DPT vaccine. Some countries 
administer an additional dose of tOPV at birth. TOPV and other 
preparations (monovalent or bivalent formulations containing types 
1 and/or 3) are now used in campaigns to supplement routine child-
hood immunization11. The recent introduction of a single dose of 
injectable polio vaccine as part of the transition to replacing tOPV 
with bivalent OPV (bOPV, types 1 and 3) may lead to changing 
serological picture for polio in Africa. Therefore, serosurveys for 
polio may have value in countries in the pre-elimination phase of 
the disease2.
Unlike for measles, polio and yellow fever where the immune 
response induced by the vaccine is indistinguishable from 
that due to natural infection,9 the presence of the antibody 
to tetanus toxin is usually, with rare exceptions, the result of 
immunization and not natural infection or subclinical 
exposure38. Therefore, serological tests for tetanus antitoxin could 
prove very helpful in ascertaining effective vaccination coverage 
for tetanus vaccine and as a surrogate for other co-administered 
vaccines. Although Tapia et al, showed a significant difference 
between tetanus antitoxin titres and receipt of the vaccine, these 
serological tests have not yet been sufficiently investigated to 
demonstrate the desired dose-response relationship between 
target markers and number of vaccine doses received39. 
Hepatitis B is thought to offer the same advantage as the testing 
of multiple antigens may help distinguish between a positive 
result due to natural infection and one following vaccination40. 
Despite the use of Hepatitis B seroprevalence data for determining 
the burden of disease and making recommendations for vaccina-
tion for several decades now41, none of the studies in this review 
investigated Hepatitis B.
Serological surveys may underestimate effective vaccination 
coverage due to waning immunity following vaccination as anti-
bodies decay over time to concentrations that may be below the 
threshold for detection of currently available tests9. The risk 
for this is higher in older children and adults. However, most 
studies included in this review were conducted in the context of 
pre- and post-vaccination campaign evaluations so they involved 
mostly younger age groups (6–72 months) and occurred shortly 
after vaccination.
One important limitation of serological surveys is the risk of or 
low participation because of the requirement of invasive samples 
e.g. venous and capillary blood for testing. Unsurprisingly, this has 
stimulated an interest in the use of less invasive samples such as 
OF42–44 and dried blood spots45,46. The use of oral fluid has been 
proposed as an alternative to overcome the risk of low participation 
due to venepuncture9. However, it appears the sensitivity of OF for 
measles antibody testing may vary according to serum measles IgG 
concentration23. In addition, serological assays of OF may be less 
sensitive in individuals with vaccine-induced immunity23,47. This is 
probably related to the serum antibody concentrations which are 
typically higher when induced by natural infection. The observed 
lower NPV for this specimen also suggests that the effectiveness 
of the vaccination programmes may be under-estimated by use 
of oral fluid assays20. Other evaluations of OF assays in Ethiopia 
and Kenya have yielded good results. However, the study in Kenya 
had no results from serum samples for comparison unlike the 
Ethiopian study that found a tight correlation between antibody 
prevalence in oral fluid and seroprevalence for measles for all 
age groups studied and for rubella in age groups <20 years24,48. 
Although these two studies highlight the potential for use of oral 
fluid as a replacement for serum in antibody prevalence surveys, 
this is an area that requires further investigation. This is impor-
tant in the light of other studies outside the region that report poor 
sensitivity of OF and the deleterious impact of environmental con-
ditions such as temperature and sample collection techniques on 
results from OF samples29,42. Although there is a longer history of 
using dried blood spots (DBS) as an alternative to venepuncture for 
serodiagnosis of many infectious diseases49, technical difficul-
ties-eluting serum from DBS, the presence of haemoglobin and 
other debris that increase background reads in ELISA assays and 
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cause lower sensitivity- have made them unpopular for vaccine 
serology1.
Our review had a few limitations. Many of the included studies 
did not justify their sample size, had a risk of residual selection 
bias in common (mainly because participants were not always ran-
domly selected or the selection process was not well described) 
and ascertainment of vaccination was not always record-based 
(risk of ascertainment and recall bias). Finally, we may have 
missed important articles published in French and/or Portuguese 
which are also relevant to sSA.
Conclusion
The use of serological data has the potential to improve ascer-
tainment of vaccination history in sSA. Serological tests of anti-
tetanus antibodies may prove to be a reliable surrogate marker of 
vaccination because they are not confounded by naturally induced 
antibodies. There are knowledge gaps in the use of serological 
surveys for tetanus and hepatitis B and whether they are likely 
to show a dose-response relationship to the number of vaccine 
doses received. This is an important area of future research. Finally, 
more investigations to assess and optimize the performance of 
non-invasive samples such as OF and DBS for vaccine 
serosurveys are also required.
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William J. Moss   
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 
Baltimore, MD, USA 
The authors conducted a systematic review of English language published papers comparing 
vaccine coverage estimates and seroprevalence in sub-Saharan Africa. Only 12 papers met the 
inclusion criteria, ten of which were on measles. 
It is mistaken to view serosurveys for vaccine-preventable diseases as a measure of vaccine 
coverage, although this appears to be the motivation for this systematic review as the “key 
outcome of interest was vaccination coverage assessed by receipt of vaccines compared to 
results of serological tests”. For reasons stated by the authors, vaccine coverage estimates 
and serological surveys, although correlated, measure two different outcomes and one 
would not expect these measures to be identical, even if the measure of vaccine coverage 
was accurate. Vaccine coverage estimates the number and timeliness of vaccine doses 
received whereas serology estimates the proportion of individuals with measurable 
antibody levels, induced by immunization or exposure to the pathogen. Serological surveys 
are the tool to estimate population immunity, not vaccination coverage. Using serology to 
adjust estimates of vaccination coverage requires sophisticated statistical methods such as 
latent class models. 
 
1. 
Serosurveys without concurrent estimates of vaccination coverage can be valuable to 
immunization programs but would not have been included in this systematic review. Such 
serosurveys can leverage biorepositories or samples collected from representative surveys 
for other purposes, and can provide information on low levels of population immunity in 
specific geographical areas or age groups. 
 
2. 
Although the authors conclude that serological surveys can be used to estimate vaccine 
exposure or coverage for tetanus toxoid, the key metric is the number of doses received. 
The issue is whether serology can be used to estimate receipt of DTP3. 
 
3. 
The “narrative” descriptions of the studies, particularly measles, can be confusing. When the 4. 
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authors report sensitivity, specificity and positive and negative predictive values, they need 
to make clear what is the gold standard and what is being compared. Several studies 
appear to be vaccine immunogenicity studies (e.g. the measles study from The Gambia for 
which they report seroconversion, and the study from Nigeria). Vaccine immunogenicity 
studies are different than studies assessing population immunity through serological 
surveys. 
 
The authors included serosurveys that used oral fluid rather than blood samples, but this 
review does not provide a sufficient evidence to assess the advantages and limitations of 
oral fluid samples. 
 
5. 
Dried blood spots are a method of storing blood samples not a method of collecting blood 
samples. One could perform venepuncture and spot the whole blood as dried blood spots. 
It is mistaken to refer to dried blood spots as a less invasive means of collecting blood or as 
an alternative to venepuncture, although frequently finger prick blood collection is used. I 
disagree that dried blood spots are “unpopular” for serological studies. 
 
6. 
The review does not address the assays used to measure seroprevalence nor the challenges 




The statement that most cases of measles are subclinical is not correct. 
 
1. 
The word “hepatitis” in “hepatitis B” should not be capitalized. 
 
2. 
The authors need to make clear why they used smallpox scar as a surrogate marker of 
measles vaccination in the study by Breman. For this study, I suggest reporting the 
proportions seropositive rather than seronegative to be consistent with the rest of the text. 
 
3. 
For the measles study in Tanzania, I do not think it appropriate to refer to the 
seroprevalence results as “effective vaccine coverage” in a setting with potential wild-type 
measles virus transmission. 
 
4. 
For the yellow fever serosurvey in Sudan, the authors should more clearly describe how the 
serosurvey was used to both describe the epidemiology of the outbreak and measure 
yellow fever vaccine coverage at the same time. 
 
5. 
I would be cautious in using the term “effective coverage” in Table 1 for diseases other than 




The authors should be more specific when they state with regard to hepatitis B: “as the 
testing of multiple antigens may help distinguish between a positive result due to natural 
infection and one following vaccination”. What antigens and what antibodies?
7. 
 
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Partly
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Yes
Is the statistical analysis and its interpretation appropriate?
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Are the conclusions drawn adequately supported by the results presented in the review?
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I confirm that I have read this submission and believe that I have an appropriate level of 
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2 London School of Hygiene & Tropical Medicine, London, UK 
This systematic review is a clearly written manuscript with targeted and fairly limited scope to look 
at the use of seroprevalence studies for determining vaccine coverage in Africa. The methods and 
results are clearly documented and the conclusions supported by their findings. 
  
As the stated aim was to identify papers where both aspects (serological status and coverage) 
were measured, the authors identified a relatively small number of studies for inclusion in their 
review. This may explain why the previous reviewer was able to identify multiple “missing” papers 
that have studied seroprevalence, but many of these may not have simultaneously evaluated 
coverage. I did check one or two of the papers suggested by Reviewer 1 and I think this may be 
the case – I would assume these studies were rejected at the initial screening of the abstract. If so, 
then, although the review may have achieved the stated aim, the usefulness of the study for those 
working in the field is more limited. As vaccine coverage data is routinely collected from most 
countries in the Region, a broader review of seroprevalence, when combined with routine 
coverage data, could have potentially provided more insight into the value of such studies. 
  
Based on the above conclusion, the authors should make the scope of the review clearer and 
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For the studies included in the review, the authors are able to make a small number of conclusions 
as to why seroprevalence studies may correlate poorly with vaccine coverage. Many of these 
aspects are not unique to Africa and I wonder if the authors could comment more about which 
aspects may be generalizable to different settings and regions. 
  
One minor comment is that haemophilus influenzae is spelt without the “e”.
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expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
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Heather Scobie  
 Global Immunization Division (GID), Centers for Disease Control and Prevention (CDC) , Atlanta, 
GA, USA 
This systematic review by Wanjiku and Adetifa has the potential to provide timely and specific 
information on serosurvey use for vaccine preventable diseases (VPDs) in Africa. In 2016, Cutts 
and Hanson made the point in their published review that sero-epidemiology an important but 
underutilized tool for designing and monitoring vaccination programs in lower and middle-income 
countries. The systematic review by Wanjiku and Adetifa complements this publication by 
providing a specific landscape analysis of the African region. While VPD serosurvey publications 
from the African Region are limited, I am concerned that the search may have missed existing 
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 1. At the time the paper was published online without review (23Feb2018), the search was already 
13 months out of date (last search 30Jan2017). Is there any reason why it was not feasible to 
update the search again closer to the publication date? Given the rapidly evolving topic area, I 
suggest including 2017 and 2018 articles up to publication time, if possible. 
 
2. Given your topic area, it seems important to include a database that captures African journals 
not indexed by Pubmed. I would suggest African Journals Online (AJO) https://www.ajol.info/ I see 
in the first Methods paragraph, reference to searching Africa Wide Information is mentioned, 
which includes AJO. But in the next paragraph, searching only PUBMED and EMBASE are 
mentioned. Please clarify what databases were used and whether Africa Wide Information was 
included. 
 
3. Confirm that you used the MESH term “Africa South of the Sahara” that would have captured 
individual country names. Otherwise, it’s not clear that papers with individual country names 
would be captured by searching “Africa” or “Sub-Saharan Africa.” 
 
4. I’m not certain that your serosurvey terms would capture all of the published literature (see 
examples in #5-8 below). Did you try including “seroprevalence”, “sero-prevalence”, 
“seroepidemiology”, “sero-epidemiology”, “population immunity”, “immunity,” “prevalence AND 
antibodies”? “Serologic*” so as to include “serological,” or better yet “sero*” so as to include the 
permutations mentioned above? For example, if I search “Nigeria polio serosurvey,” I get zero hits, 
but if I search “Nigeria polio seroprevalence,” I get 13 hits. 
 
5. I find many polio serosurveys from Nigeria not referenced in the paper (see below, which isn't a 







6. A review of measles and rubella serosurveys was published recently: Dimech and Mulders, 2016 
7. It looks like at least one articles captured in that review may have been missed here:
Enquselassie et al. Seroepidemiology of measles in Addis Ababa, Ethiopia: Implications for 
control through vaccination. Epidemiology and Infection Volume 130, Issue 3, June 2003, 
Pages 507-519 8
○
7. This published review by Breakwell et al. appears to summarize HepB serosurveys including 
vaccination status in the Region: http://www.panafrican-med-
journal.com/content/series/27/3/17/full/ 9. The authors of the paper under review state “No study 
looked at Hepatitis B.” Can you please comment on why the HepB papers in Table 3 by Breakwell 
et al. were not captured for inclusion? It's unclear if HepB Surface Antigen testing was 
systematically missed because it is not an antibody test. These studies are more typically titled 
“prevalence of HepB surface antigen”. This is an additional Hep B reference that looks like it should 
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be included: Olayinka et al. “Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey.” 
Am. J. Trop. Med. Hyg., 95(4), 2016, pp. 902–907 10. 
 
8. For tetanus, I’m aware of serosurveys of adult women that included vaccination coverage in 
Central African Republic and Burundi which likely should have been included:
Deming MS, Roungou JB, Kristiansen M, Heron I, Yango A, Guenengafo A, et al. Tetanus 
toxoid coverage as an indicator of serological protection against neonatal tetanus. Bulletin 
of the World Health Organization. 2002;80(9):696-703. 11
○
World Health Organization. Expanded programme on immunization--estimating tetanus 
protection of women by serosurvey. Wkly Epidemiol Rec. 1996;71(16):117-24. 12
○
9. I’m surprised that in Figure 1 only three articles were excluded for being serosurveys not 
including vaccination coverage. I would guess that the majority of published serosurveys in Africa 
did not collect vaccination coverage (e.g., rubella serosurveys of adult women). Other articles may 
not report coverage in the abstract but do report it in the full text. An example would be Aboud et 
al., 2000 13. Inability to capture these articles should be a stated limitation of your review. If you 
re-categorized the 1031 articles that were “non-relevant” into smaller groups, and the number 
excluded because of not including vaccination coverage was high, you may be able to recommend 
inclusion of vaccination status in serosurveys where possible to inform interpretation of results 




1. MacNeil et al 201414 summarizes the limitations of using serosurveys to assess vaccination 
coverage. In my experience, the limitations are not “well known” as the authors state in the 
introduction. A major result described in the abstract is discordance of coverage and serosurvey 
results for diseases where natural infection causes immunity. This limitation of serosurveys 
(inability to discriminate immunity from natural infection and vaccination, except for tetanus) 
seems worth describing in the introduction. 
 
2. Another limitation of serosurveys that is not mentioned is misclassification bias related to use of 
non-gold standard tests, e.g., ELISAs with poor sensitivity and poor specificity. This issue is also 
discussed in MacNeil et al 201414 and deserves mention. It is especially problematic for tetanus 
where indirect ELISAs have challenges to discriminate at lower antibody titers around the 
threshold for seroprotection, discussed in Scobie 201615, the WHO Immunological Basis of 
Immunization Tetanus Module, and early literature:
Hendriksen CF, vd Gun JW, Nagel J, Kreeftenberg JG. 1988. The toxin binding inhibition test 
as a reliable in vitro alternative to the toxin neutralization test in mice for the estimation of 
tetanus antitoxin in human sera. J Biol Stand 16:287–297. 16
○
Kristiansen M, Aggerbeck H, Heron I. 1997. Improved ELISA for determination of anti-
diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS 105:843–853. 17
○
Dokmetjian J, Della Valle C, Lavigne V, de Lujan CM, Manghi MA. 2000. A possible 
explanation for the discrepancy between ELISA and neutralizing antibodies to tetanus toxin. 
Vaccine 18:2698–2703. 18
○
Simonsen O, Schou C, Heron I. 1987. Modification of the ELISA for the estimation of tetanus 
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